GFAP and nervous system disorder: In conclusion, this study successfully demonstrated that the GFAP Chemiluminescent Enzyme Immunoassay (CLEIA) exhibited the convenience and good analytical performance necessary for GFAP measurements to aid in the differential diagnosis of neurological disorders.